Neuroblastoma (NB) is the most common extracranial solid embryonic tumor in children. The age of patient, the prevalence of the tumor process and the molecular genetic profile formed the basis of risk-adapted therapy protocols. High-risk patients receive complex treatment, including various combinations of chemotherapy drugs, surgical removal of the tumor, radiation and radioisotope therapy. Since the end of the 90s of the last century, immunotherapy has been introduced into clinical practice as a post-consolidation phase with the aim of affecting the minimal residual tumour mass. GD2-targeted drugs are used as a therapeutic agent for immunotherapy. An important aspect is the study of the early and late toxicity of this therapeutic method. The main side effects include fever, neuropathic pain, allergic reactions, and capillary leak syndrome. The article presents the analysis of literature data on toxic effects arising from immunotherapy (dinutuximab beta), as well and a description of clinical case report of rare specific pathology – ophthalmic complications, which include mydriasis and accommodation disorder up to paresis. The pathogenesis of these disorders is described in the literature as a parasympathetic deficiency, realized through exposure to anti-GD2 drugs, and is leveled after the end of treatment. Given the reversible nature of the disorders, the occurrence of ophthalmic complications does not require the abolition of immunotherapy, however, careful ophthalmological monitoring of the dynamics of pathological manifestations and timely symptomatic correction of the revealed changes are necessary. This information is very important not only for pediatric oncologists/hematologists, but also for ophthalmologists and pediatricians.
17 July 2026 in Russian journal of hematology and transfusiology
Introduction . Primary vitreoretinal lymphoma (PVRL) is a subtype of lymphoma of immune-privileged organs. Both diagnosis and treatment decisions pose significant challenges for PVRL. Aim : to present a clinical observation in treating patients with PVRL and possibilities for improving diagnosis and treatment outcomes. Main Findings . Since 2024, two patients with PVRL, aged 66 and 75 years, have been treated at the National Medical Research Center for Hematology. Modern diagnostic methods based on molecular analysis to detect mutations in the MYD88/ CD79b genes in vitreous fluid were used to establish the diagnosis. A two-stage approach was used for treatment: remission induction using the R-MPV protocol with the addition of lenalidomide and ibrutinib, followed by consolidation auto-HCT in a conditioning regimen according to the “BBC” program. Disease relapses were detected in both patients early after auto-HCT. Thus, for timely diagnosis, it is advisable to implement minimally invasive methods for studying the molecular profile of PVRL. The development of new therapeutic approaches, integrating innovative cell therapy into first-line treatment and the use of thiotepa-based conditioning regimens, is also advisable.
Modern methods of treatment have significantly increased the survival rate of children with oncohematological diseases, and along with it the importance of preserving their quality of life. More than half of patients receiving long-term steroid therapy suffer from glaucoma, which reduces visual acuity. This review analyzes the literature on the patterns of glaucoma development in patients receiving steroid therapy, the results of anatomical, as well as physiological and biochemical changes in the anterior chamber angle leading to the development of glaucoma.
13 December 2024 in Pediatric Hematology/Oncology and Immunopathology
Monitoring of viral “load” in intraocular fluid and intravitreal injections (IVIs) of antiviral drugs along with systemic antiviral therapy is an effective measure of control of cytomegalovirus retinitis in hematopoietic stem cell (HSC) recipients, but the safety of this method in children has not been studied. Complications of serial intraocular fluid sampling and IVIs of antiviral drugs (pain, hemorrhage, corneal erosion) were evaluated after 585 IVIs in 48 pediatric HSC recipients. The study was approved by the Independent Ethics Committee and the Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation. Pain was assessed using the visual analog pain scale, and ophthalmoscopy was performed before the IVI and the day after it to detect other complications (1174 exams). Pain developing immediately after the IVI was shown to be an almost inevitable consequence of the procedure (43 (96%) of 45 patients; after 92% of injections) and was independent of the drug administered (ganciclovir vs foscarnet) or its concentration. The most common complication was subconjunctival hemorrhage of varying severity (16%), with rare complications represented by hyphema (0.3%) and corneal erosion. Serial IVIs of antiviral drugs with intraocular fluid sampling is an effective and safe method of treatment of cytomegalovirus retinitis in pediatric recipients of allogeneic HSC, but it inevitably causes post-manipulation pain requiring analgesia.
5 October 2025 in Russian journal of hematology and transfusiology
Introduction. Cytomegalovirus retinitis (CMVR) is a necrotizing disease of the retina that can cause irreversible blindness. An increase in the number of CMVR episodes increases the likelihood of developing irreversible blindness. Reducing the risk of CMVR recurrence will improve the effectiveness of visual rehabilitation for this category of patients. Aim: To study the patterns and risk factors for the development of CMVR recurrence in children who are recipients of hematopoietic stem cells. Materials and methods. The study included 37 patients aged 0 to 21 years (62 eyes) who had undergone CMVR and hematopoietic stem cell transplantation and received a series of intravitreal injections (IVI) of antiviral drugs. CMVR recurrences occurred in seven patients. In 3 patients, there was a recurrence in 1 eye, in 4 — in both eyes. Of the 62 eyes, 51 had no recurrences, 6 had one recurrence, and 5 had more than one recurrence. A recurrence was diagnosed in 23 out of 81 episodes. Remission was considered achieved when the absence of cytomegalovirus DNA was confi rmed in a sample of aqueous humor taken from the anterior chamber of the eye and/or upon complete healing of CMVR lesions as determined by ophthalmoscopy. Results. Discontinuation of IV antiviral drugs based on negative aqueous humor PCR results reduces the likelihood of recurrence by more than 16 times compared to a decision based on ophthalmoscopic data (p-value = 0.011) and by more than 2 times compared with non-zero PCR results. Conclusion. The recurrent nature of the course of CMVR is associated with the replication of virus copies inside the eye. Elimination of copies of the virus from the intraocular fl uid reduces the likelihood of developing a CMVR recurrence.
29 June 2019 in Pediatric Hematology/Oncology and Immunopathology
Modern technologies of treatment of children with oncohaematological diseases allowed to noticebly increase the survival indexes in this group of patients, enhancing the value of maintenance of their life quality. More than half of those who received long-term steriod and radiation treatment develop cataract that causes decrease in vision. In this review we represent data concerning mechanisms of cataract formation in patients after steriod and radiation treatment, results of anatomical, physiological and biochemical studies of the lens as well as metabolic changes in aqueous humor leading to cataract formation.